Compare LGIH & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | QURE |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2013 |
| Metric | LGIH | QURE |
|---|---|---|
| Price | $40.56 | $26.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $75.90 | $45.00 |
| AVG Volume (30 Days) | 415.7K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | $13,107,000.00 |
| Revenue This Year | $2.32 | $126.12 |
| Revenue Next Year | $17.94 | $200.43 |
| P/E Ratio | $487.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.55 | $8.73 |
| 52 Week High | $69.42 | $71.50 |
| Indicator | LGIH | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 67.45 |
| Support Level | $34.71 | $21.16 |
| Resistance Level | $41.50 | $28.63 |
| Average True Range (ATR) | 2.33 | 2.27 |
| MACD | -0.64 | 0.72 |
| Stochastic Oscillator | 1.03 | 76.65 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.